Aptevo Therapeutics Inc. (APVO)

Every figure this model derived for APVO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2022-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 29,000 PaymentsToAcquirePropertyPlantAndEquipment 2022-12-31
cash 18,989,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 10,798,000 AssetsCurrent 2026-06-30
current liabilities 5,188,000 LiabilitiesCurrent 2026-06-30
equity 6,041,000 StockholdersEquity 2026-06-30
revenue 3,114,000 RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up APVO on one particular measure came for.

RatioValue
current ratio2.08
current ratio reported2.08
deferred revenue growth266.5
growth cv4.08
revenue growth-74.67
revenue growth per share-74.67
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about APVO's figures. Written by the derivation as it ran, not added afterwards.